Reduced paraoxonase 1 activity as a marker for severe coronary artery disease

Chiyan Zhou, Jia Cao, Liang Shang, Chuanfeng Tong, Hanling Hu, Hui Wang, Daping Fan, Hong Yu, Chiyan Zhou, Jia Cao, Liang Shang, Chuanfeng Tong, Hanling Hu, Hui Wang, Daping Fan, Hong Yu

Abstract

Paraoxonase-1 (PON1), a high-density-lipoprotein- (HDL-) associated enzyme, has the potential to protect against atherogenesis. We examine the relationships between plasma PON1 activity and the progression of atherosclerosis as well as coronary artery disease (CAD). Fasting blood samples were collected from female apolipoprotein E-deficient (apoE(-/-)) mice and 149 patients undergoing coronary angiography for the biochemical parameters measurement. The severity of CAD was defined using angiographic Gensini score (GSS). Compared to 3-month-old apoE(-/-) mice, aged mice had significantly lower PON1 activity, which is negatively correlated with the size of atherosclerotic lesion and plasma interleukin-6 (IL-6) and tumor necrosis factor α (TNF- α ) levels. In study patients, PON1 activity was correlated with age, sex, and HDL-cholesterol, apolipoprotein AI, and high-sensitivity C-reactive protein (hs-CRP) levels and was significantly lower in CAD group than that in non-CAD control group. Interestingly, PON1 activity in severe CAD group (GSS > 40) was further significantly reduced compared to those in mild and moderate subgroups (GSS ≤ 40) (P < 0.01). There is a significant correlation between PON1 activity and the severity of CAD as assessed by GSS (r = -0.393, P < 0.001). PON1 activity may be a potential biomarker for the severity of CAD.

Figures

Figure 1
Figure 1
Atherosclerotic lesion areas in proximal aortas of apoE−/− mice with different ages. (a) Representative atherosclerotic lesions in cross-sections of proximal aortas stained with oil-red O. (b) Representative en face aortas from 3 months to 18 months. Quantitation of the mean lesion area of aortic sinus (c) and percentage lesion area in the aorta by en face analysis (d).
Figure 2
Figure 2
Correlation between PON1 activity and the severity of atherosclerosis in patients. The linear regression analysis revealed a significant correlation between PON1 activity and the severity of atherosclerosis as assessed by the angiographic Gensini score (GSS) (Pearson correlation coefficient r = −0.393, associated P < 0.001).

References

    1. Hansson GK. Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine. 2005;352(16):1685–1695.
    1. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(1):29–38.
    1. Tabet F, Rye K-A. High-density lipoproteins, inflammation and oxidative stress. Clinical Science. 2009;116(2):87–98.
    1. Getz GS, Reardon CA. Paraoxonase, a cardioprotective enzyme: continuing issues. Current Opinion in Lipidology. 2004;15(3):261–267.
    1. MacKness B, MacKness M. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Advances in Experimental Medicine and Biology. 2010;660:143–151.
    1. Shih DM, Xia Y-R, Wang X-P, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. Journal of Biological Chemistry. 2000;275(23):17527–17535.
    1. Ng DS, Chu T, Esposito B, Hui P, Connelly PW, Gross PL. Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia. Cardiovascular Pathology. 2008;17(4):226–232.
    1. Tward A, Xia Y-R, Wang X-P, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002;106(4):484–490.
    1. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(7):1545–1550.
    1. Wang M, Lang X, Cui S, et al. Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease risk. DNA and Cell Biology. 2012;31:975–982.
    1. Zhao Y, Ma Y, Fang Y, et al. Association between PON1 activity and coronary heart disease risk: a meta-analysis based on 43 studies. Molecular Genetics and Metabolism. 2012;105(1):141–148.
    1. Tartan Z, Orhan G, Kasikçioglu H, et al. The role of paraoxonase (PON) enzyme in the extent and severity of the coronary artery disease in type-2 diabetic patients. Heart and Vessels. 2007;22(3):158–164.
    1. Balcerzyk A, Zak I, Krauze J. Protective effect of R allele of PON1 gene on the coronary artery disease in the presence of specific genetic background. Disease Markers. 2008;24(2):81–88.
    1. Thyagarajan B, Jacobs DR, Jr., Carr JJ, et al. Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clinical Chemistry. 2008;54(4):738–746.
    1. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. American Journal of Cardiology. 1983;51(3):p. 606.
    1. Handa K, Kono S, Saku K, et al. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis. 1989;77(2-3):209–213.
    1. Yu H, Zhang W, Yancey PG, et al. Macrophage apolipoprotein E reduces atherosclerosis and prevents premature death in apolipoprotein E and scavenger receptor-class BI double-knockout mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(1):150–156.
    1. Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, Getz GS. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. Journal of Lipid Research. 2003;44(4):780–792.
    1. Perla-Kajan J, Jakubowski H. Paraoxonase 1 and homocysteine metabolism. Amino Acids. 2012;43(4):1405–1417.
    1. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E- deficient mice created by homologous recombination in ES cells. Cell. 1992;71(2):343–353.
    1. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258(5081):468–471.
    1. Feingold KR, Memon RA, Moser AH, Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis. 1998;139(2):307–315.
    1. Kotur-Stevuljevic J, Spasic S, Jelic-Ivanovic Z, et al. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clinical Biochemistry. 2008;41(13):1067–1073.
    1. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292–2333.
    1. Rainwater DL, Rutherford S, Dyer TD, et al. Determinants of variation in human serum paraoxonase activity. Heredity. 2009;102(2):147–154.
    1. Blatter Garin M-C, Moren X, James RW. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. Journal of Lipid Research. 2006;47(3):515–520.
    1. Rozek LS, Hatsukami TS, Richter RJ, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. Journal of Lipid Research. 2005;46(9):1888–1895.
    1. Sarkar PD, Shivaprakash TM, Madhusudhan B. Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease. Clinica Chimica Acta. 2006;373(1-2):77–81.
    1. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacological Reviews. 2006;58(3):342–374.
    1. Navab M, Reddy ST, van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nature Reviews Cardiology. 2011;8(4):222–232.
    1. Zhao Y, Wang R, Ma X, et al. Distribution of C-reactive protein and its association with cardiovascular risk factors in a population-based sample of Chinese. Disease Markers. 2010;28(6):333–342.
    1. Sarwar N, Thompson AJ, Di Angelantonio E. Markers of inflammation and risk of coronary heart disease. Disease Markers. 2009;26(5-6):217–225.
    1. Mackness B, Hine D, McElduff P, Mackness M. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis. 2006;186(2):396–401.
    1. Mineo C, Shaul PW. PON-dering differences in HDL function in coronary artery disease. Journal of Clinical Investigation. 2011;121(7):2545–2548.
    1. Fuhrman B, Gantman A, Aviram M. Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis. 2010;211(1):61–68.
    1. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. Journal of Clinical Investigation. 2011;121(7):2693–2708.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться